Praxis Precision Medicines (PRAX) Cash from Investing Activities (2021 - 2026)

Praxis Precision Medicines' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$344.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 574.2% year-over-year to -$344.3 million; the TTM figure through Mar 2026 stood at -$604.4 million (down 190.09% YoY), while the FY2025 annual figure was -$311.1 million, down 25.21% from the prior year.
• Cash from Investing Activities was -$344.3 million for Q1 2026 at Praxis Precision Medicines, down from -$328.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $50.4 million in Q3 2025 to a low of -$344.3 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$48.0 million across 5 years, with a median of $2.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 497.66% in 2023, then slumped 21736.0% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $22.6 million in 2022, then slumped by 100.22% to -$50000.0 in 2023, then plunged by 21736.0% to -$10.9 million in 2024, then sank by 2907.79% to -$328.4 million in 2025, then declined by 4.84% to -$344.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$344.3 million (Q1 2026), -$328.4 million (Q4 2025), and $50.4 million (Q3 2025), per Business Quant data.